| Product Unit Size | Cost | Quantity | Stock |
|---|
Dutasteride is an inhibitor of 5-α-reductase (types 1/2) that is clinically used to treat benign prostatic hyperplasia (BPH), often co-administered with tamsulosin. Dutasteride exhibits anti-inflammatory and anticancer chemotherapeutic activities. In prostatic cells, dutasteride induces apoptosis and inhibits cell proliferation. In vivo, this compound decreases prostate volume. In animal models, dutasteride suppresses growth of prostate tumors.
| Cas No. | 164656-23-9 |
|---|---|
| Purity | ≥99% |
| Formula | C27H30F6N2O2 |
| Formula Wt. | 528.53 |
| Synonym | Avodart |
| Solubility | Soluble in ethanol (44 mg/ml), methanol (64 mg/ml), polyethylene glycol 400 (3 mg/ml), and DMSO (62 mg/ml at 25° C 117mM). Insoluble in water. |
| Appearance | White to off white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Tsujimura A, Fukuhara S, Soda T, et al. Histologic evaluation of human benign prostatic hyperplasia treated by dutasteride: a study by xenograft model with improved severe combined immunodeficient mice. Urology. 2015 Jan;85(1):274.e1-8. PMID: 25444635.
Barkin J. Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability. Patient Prefer Adherence. 2011;5:483-90. PMID: 22003286.
Arena F. Dutasteride in the treatment of hormone refractory prostate cancer. Minerva Urol Nefrol. 2008 Jun;60(2):71-6. PMID: 18500220.